JP2015533176A5 - - Google Patents

Download PDF

Info

Publication number
JP2015533176A5
JP2015533176A5 JP2015537018A JP2015537018A JP2015533176A5 JP 2015533176 A5 JP2015533176 A5 JP 2015533176A5 JP 2015537018 A JP2015537018 A JP 2015537018A JP 2015537018 A JP2015537018 A JP 2015537018A JP 2015533176 A5 JP2015533176 A5 JP 2015533176A5
Authority
JP
Japan
Prior art keywords
composition
ezh2
pharmaceutically acceptable
compound according
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015537018A
Other languages
English (en)
Japanese (ja)
Other versions
JP6461802B2 (ja
JP2015533176A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/065126 external-priority patent/WO2014062732A1/en
Publication of JP2015533176A publication Critical patent/JP2015533176A/ja
Publication of JP2015533176A5 publication Critical patent/JP2015533176A5/ja
Application granted granted Critical
Publication of JP6461802B2 publication Critical patent/JP6461802B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015537018A 2012-10-15 2013-10-15 置換ベンゼン化合物 Expired - Fee Related JP6461802B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261714140P 2012-10-15 2012-10-15
US201261714145P 2012-10-15 2012-10-15
US61/714,145 2012-10-15
US61/714,140 2012-10-15
US201361780703P 2013-03-13 2013-03-13
US61/780,703 2013-03-13
US201361786277P 2013-03-14 2013-03-14
US61/786,277 2013-03-14
PCT/US2013/065126 WO2014062732A1 (en) 2012-10-15 2013-10-15 Substituted benzene compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018028891A Division JP2018087238A (ja) 2012-10-15 2018-02-21 置換ベンゼン化合物

Publications (3)

Publication Number Publication Date
JP2015533176A JP2015533176A (ja) 2015-11-19
JP2015533176A5 true JP2015533176A5 (cg-RX-API-DMAC10.html) 2016-12-01
JP6461802B2 JP6461802B2 (ja) 2019-01-30

Family

ID=50475881

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015537019A Expired - Fee Related JP6461803B2 (ja) 2012-10-15 2013-10-15 置換ベンゼン化合物
JP2015537018A Expired - Fee Related JP6461802B2 (ja) 2012-10-15 2013-10-15 置換ベンゼン化合物
JP2018028891A Withdrawn JP2018087238A (ja) 2012-10-15 2018-02-21 置換ベンゼン化合物
JP2018028907A Active JP6559275B2 (ja) 2012-10-15 2018-02-21 置換ベンゼン化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015537019A Expired - Fee Related JP6461803B2 (ja) 2012-10-15 2013-10-15 置換ベンゼン化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018028891A Withdrawn JP2018087238A (ja) 2012-10-15 2018-02-21 置換ベンゼン化合物
JP2018028907A Active JP6559275B2 (ja) 2012-10-15 2018-02-21 置換ベンゼン化合物

Country Status (23)

Country Link
US (8) US9006242B2 (cg-RX-API-DMAC10.html)
EP (4) EP2906538A4 (cg-RX-API-DMAC10.html)
JP (4) JP6461803B2 (cg-RX-API-DMAC10.html)
KR (2) KR102057366B1 (cg-RX-API-DMAC10.html)
CN (3) CN110041250A (cg-RX-API-DMAC10.html)
AR (1) AR093244A1 (cg-RX-API-DMAC10.html)
AU (2) AU2013331380B2 (cg-RX-API-DMAC10.html)
BR (2) BR112015008480A2 (cg-RX-API-DMAC10.html)
CA (2) CA2888021A1 (cg-RX-API-DMAC10.html)
CL (2) CL2015000944A1 (cg-RX-API-DMAC10.html)
HK (2) HK1213264A1 (cg-RX-API-DMAC10.html)
IL (4) IL238135B (cg-RX-API-DMAC10.html)
MX (2) MX2015004721A (cg-RX-API-DMAC10.html)
MY (1) MY180311A (cg-RX-API-DMAC10.html)
NZ (2) NZ706739A (cg-RX-API-DMAC10.html)
PE (2) PE20150886A1 (cg-RX-API-DMAC10.html)
PH (2) PH12015500800A1 (cg-RX-API-DMAC10.html)
RU (2) RU2662436C2 (cg-RX-API-DMAC10.html)
SG (3) SG11201502803VA (cg-RX-API-DMAC10.html)
TW (2) TWI588131B (cg-RX-API-DMAC10.html)
UA (2) UA115074C2 (cg-RX-API-DMAC10.html)
WO (2) WO2014062733A2 (cg-RX-API-DMAC10.html)
ZA (2) ZA201502526B (cg-RX-API-DMAC10.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
IL308613A (en) 2012-10-15 2024-01-01 Epizyme Inc Cancer treatment methods
US9006242B2 (en) 2012-10-15 2015-04-14 Epizyme, Inc. Substituted benzene compounds
RU2015127822A (ru) 2012-12-13 2017-01-16 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы энхансера гомолога 2 белка zeste
EP2935214B1 (en) * 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
EP3112366B1 (en) 2013-03-14 2018-02-28 Janssen Pharmaceutica NV P2x7 modulators
CN105026395B (zh) 2013-03-14 2018-07-20 勃林格殷格翰国际有限公司 取代的氮杂双环酰胺类组织蛋白酶c抑制剂及其药物组合物和制药用途
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9556157B2 (en) 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EA038869B1 (ru) 2013-10-16 2021-10-29 Эпизим, Инк. Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
CN116019921A (zh) 2013-12-06 2023-04-28 Epizyme股份有限公司 用于治疗癌症的组合疗法
LT3157527T (lt) 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitoriai, skirti limfomos gydymui
EA034015B1 (ru) 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
US20180118749A1 (en) 2014-09-12 2018-05-03 Janssen Pharmaceutica Nv P2x7 modulators
NZ728684A (en) 2014-09-12 2022-09-30 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
CA2963149A1 (en) * 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
MX383484B (es) 2014-11-17 2025-03-11 Epizyme Inc Método para tratar el cáncer.
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
SG10201902664RA (en) 2015-04-20 2019-04-29 Epizyme Inc Combination therapy for treating cancer
MX387885B (es) 2015-06-10 2025-03-19 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
JP2019503391A (ja) 2016-01-29 2019-02-07 エピザイム,インコーポレイティド 癌を処置するための併用療法
WO2017184999A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
CN108699002B (zh) * 2016-11-11 2021-11-09 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN111093660A (zh) 2017-09-05 2020-05-01 Epizyme股份有限公司 用于治疗癌症的组合疗法
BR112020015583B1 (pt) 2018-01-31 2022-12-06 Mirati Therapeutics, Inc Composto, composição farmacêutica e seu uso para tratar câncer
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
WO2020065613A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
KR20210069079A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
WO2020219448A1 (en) 2019-04-22 2020-10-29 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド T細胞療法とzesteホモログ2エンハンサー(EZH2)阻害剤との併用療法および関連方法
CN114555596B (zh) 2019-09-30 2025-02-25 詹森药业有限公司 放射性标记的mgl pet配体
CN111303133A (zh) * 2020-03-25 2020-06-19 清华大学 降解ezh2蛋白的小分子化合物
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
EP4393490A4 (en) * 2021-08-30 2025-08-27 Jiangsu Hengrui Pharmaceuticals Co Ltd USE OF AN EZH2 INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF T-CELL LYMPHOMA

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd N−シアノ−n′−置換−アリールカルボキシイミダミド化合物の製造法
RU2128644C1 (ru) 1993-12-27 1999-04-10 Эйсай Ко., Лтд. Производные антраниловой кислоты или их фармакологически приемлемые соли, промежуточные продукты для их получения и лекарственный препарат на их основе
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
BR9914207A (pt) 1998-09-30 2001-07-03 Procter & Gamble Ceto-amidas 2-substituìdas
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DK1357111T3 (da) 2000-12-28 2009-11-02 Shionogi & Co 2-pyridonderivater med affinitet for cannabinoid type 2-receptor
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US20050101590A1 (en) 2002-02-19 2005-05-12 Kiyoshi Yasui Antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
EP1575596B1 (en) 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
WO2004112719A2 (en) 2003-06-19 2004-12-29 Smithkline Beecham Corporation Chemical compounds
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
PL1663194T3 (pl) 2003-08-26 2011-01-31 Merck Hdac Res Llc Zastosowanie SAHA do leczenia międzybłoniaka
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
WO2005094816A1 (en) 2004-03-11 2005-10-13 Actelion Pharmaceuticals Ltd Indol-1-yl-acetic acid derivatives
CN1286973C (zh) 2004-04-12 2006-11-29 上海第二医科大学附属瑞金医院 一种组蛋白甲基转移酶及其制备方法
WO2005118796A2 (en) 2004-06-01 2005-12-15 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7923219B2 (en) 2005-06-02 2011-04-12 The University Of North Carolina At Chapel Hill Ubiquitin E3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1940821B1 (de) 2005-10-19 2013-03-20 Grünenthal GmbH Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
WO2007050347A1 (en) 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors
EP1941060B1 (en) 2005-10-28 2012-02-29 The University of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
WO2007072225A2 (en) 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007087015A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
CN101443007A (zh) 2006-05-15 2009-05-27 Irm责任有限公司 Terephthalamate化合物和组合物及其作为hiv整合酶抑制剂的用途
CA2652634A1 (en) 2006-05-18 2007-11-29 Amphora Discovery Corporation Certain substituted quinolones, compositions, and uses thereof
EP2086318A4 (en) 2006-10-10 2009-12-23 Burnham Inst Medical Research NEUROPROTECTIVE COMPOSITIONS AND CORRESPONDING METHODS
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008109534A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US20090012031A1 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
CN101754955A (zh) 2007-07-16 2010-06-23 雅培制药有限公司 作为蛋白激酶抑制剂的吲唑、苯并异*唑和苯并异噻唑化合物
US8247401B2 (en) 2007-10-31 2012-08-21 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
KR101608096B1 (ko) 2008-01-23 2016-03-31 브리스톨-마이어스 스큅 컴퍼니 4-피리디논 화합물 및 암을 위한 그의 용도
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
WO2010017355A2 (en) 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
CA2756152A1 (fr) 2009-03-24 2010-09-30 Sanofi Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US8329149B2 (en) 2009-12-30 2012-12-11 Avon Products, Inc. Topical lightening composition and uses thereof
EP2566328B1 (en) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
CN102970869B (zh) 2010-05-07 2014-07-16 葛兰素史密斯克莱有限责任公司 吲哚
JP5889875B2 (ja) 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC アザインダゾール
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012075080A1 (en) 2010-12-01 2012-06-07 Glaxosmithkline Llc Indoles
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
US8791782B2 (en) * 2011-01-28 2014-07-29 Uses, Inc. AC power conditioning circuit
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CN103987842A (zh) 2011-09-30 2014-08-13 葛兰素史密斯克莱有限责任公司 治疗癌症的方法
JP6321619B2 (ja) * 2012-03-12 2018-05-09 エピザイム インコーポレイテッド ヒトezh2の阻害剤およびその使用方法
IL308807B2 (en) * 2012-04-13 2025-08-01 Epizyme Inc Combination therapy for treating cancer
PL2836491T3 (pl) * 2012-04-13 2017-08-31 Epizyme, Inc. Postać soli inhibitora ludzkiej metylotransferazy histonowej EZH2
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US9006242B2 (en) 2012-10-15 2015-04-14 Epizyme, Inc. Substituted benzene compounds
IL308613A (en) 2012-10-15 2024-01-01 Epizyme Inc Cancer treatment methods

Similar Documents

Publication Publication Date Title
JP2015533176A5 (cg-RX-API-DMAC10.html)
RU2015118135A (ru) Содержащие заместители бензольные соединения
JP2017008088A5 (cg-RX-API-DMAC10.html)
JP2009514880A5 (cg-RX-API-DMAC10.html)
JP2009514881A5 (cg-RX-API-DMAC10.html)
JP2020514311A5 (cg-RX-API-DMAC10.html)
JP2016533366A5 (cg-RX-API-DMAC10.html)
PE20170312A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
JP2012082234A5 (cg-RX-API-DMAC10.html)
JP2016515561A5 (cg-RX-API-DMAC10.html)
JP2012153722A5 (cg-RX-API-DMAC10.html)
JP2013542261A5 (cg-RX-API-DMAC10.html)
JP2015533177A5 (cg-RX-API-DMAC10.html)
JP2017517520A5 (cg-RX-API-DMAC10.html)
WO2015154064A3 (en) Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
JP2016501221A5 (cg-RX-API-DMAC10.html)
JP2018524347A5 (cg-RX-API-DMAC10.html)
JP2018526376A5 (cg-RX-API-DMAC10.html)
JP2014511892A5 (cg-RX-API-DMAC10.html)
RU2017143776A (ru) Пролекарства альвоцидиба, имеющие повышенную биодоступность
NZ706999A (en) Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
JP2019506392A5 (cg-RX-API-DMAC10.html)
JP2018536636A5 (cg-RX-API-DMAC10.html)
JP2017528475A5 (cg-RX-API-DMAC10.html)